Prosecution Insights
Last updated: November 11, 2026
Application No. 18/563,448

ADJUNCTIVE D-CYCLOSERINE AUGMENTATION OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) THERAPY FOR MAJOR DEPRESSIVE DISORDER

Non-Final OA §102§112
Filed
Nov 22, 2023
Priority
May 27, 2021 — provisional 63/193,643 +1 more
Examiner
BORALSKY, LUKE ALAN
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mcgrx Corp.
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
4 granted / 6 resolved
+6.7% vs TC avg
Strong +44% interview lift
Without
With
+44.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
48 currently pending
Career history
55
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
26.7%
-13.3% vs TC avg
§102
13.3%
-26.7% vs TC avg
§112
39.4%
-0.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 6 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of Group (II) in the reply filed on 7/27/2026 is acknowledged. The traversal is on the ground(s) that (Remarks, page 2) “each of the independent claims identified in the Examiner's alleged Groups I-III are directed to a specific combination of treatment with D-cycloserine (DCS) and transcranial magnetic stimulation (TMS). Thus, the special technical feature of the present application is more appropriately characterized as administration of the specific and discreet combination of DCS and TMS, which the Mataix-Cols reference does not address.” Applicant further argues (Remarks, page 2-3) that the “alleged groups are not independent or distinct, and relate to the same inventive concept, as claimed” and “would not be a serious search burden on the examiner”. This is found partially persuasive. The independent claims of the instant application are directed to a combination of treatment with DCS and TMS, whereas the Mataix-Cols reference only addresses the use of D-cycloserine, as Applicant points out. However, the invention of Group III is independent and distinct from the inventions of Group I and II, which the Examiner will address in a new restriction requirement. The restriction requirement filed 1/26/2025 is hereby withdrawn and a new restriction requirement is set forth below: REQUIREMENT FOR UNITY OF INVENTION As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (“requirement of unity of invention”). Where a group of inventions is claimed in a national stage application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression “special technical features” shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim. See 37 CFR 1.475(e). WHEN CLAIMS ARE DIRECTED TO MULTIPLE CATEGORIES OF INVENTIONS As provided in 37 CFR 1.475(b), a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said process; or (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process. Otherwise, unity of invention might not be present. See 37 CFR 1.475(c). Restriction is required under 35 U.S.C. 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Group (I), claim(s) 1-3, 5, 7-12, drawn to a method of treating Major Depressive Disorder (MDD) comprising administering adjunctive D-cycloserine (DCS) to augment transcranial magnetic stimulation; Group (II), claim(s) 13, drawn to a method of prolonging the effects of transcranial magnetic simulation comprising administering DCS or an N-methyl-D-aspartate receptor agonist or partial agonist. The claims herein lack unity of invention under PCT rule 13.1 and 13.2 since, under 37 CFR 1.475(a) Group I -Group II lack unity of invention since under 37 CFR 1.475: Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features…those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: No Shared Technical Feature Common: Groups I and II lack unity of invention because the groups do not share the same or corresponding technical feature. In the instant case, for example, Group I is drawn to treating MDD using D-cycloserine (a partial agonist) in combination with transcranial magnetic stimulation. On the other hand, the invention of Group II is drawn to prolonging the effects of transcranial magnetic stimulation comprising administering D-cycloserine or an NMDA agonist or partial agonist. Group II is, in fact, not drawn to treating MDD at all (like Group I is), and the invention of Group II is additionally drawn to all NMDA agonists or partial agonists (which Group I is not). Unity is thus lacking among Groups I and II. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper. The requirement is deemed proper and is therefore made FINAL. Application and Claims Status Examiner notes that in Applicant Remarks, filed 7/27/2026, Applicant write “Claims 1-13 are pending”. This is not accurate, as claims 1-3, 5, and 7-13 are the currently pending claims, while claims 4 and 6 have been cancelled. Claim 13 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 7/27/2026. Therefore, claims 1-3, 5, and 7-13 are currently pending and claims 1-3, 5, and 7-12 are examined herein. Priority The instant application is a 35 U.S.C. § 371 national stage filing of No. PCT/CA2022/050839, filed May 26, 2022, which claims the benefit of U.S. Provisional Application No. 63/193,643, filed May 27, 2021. Information Disclosure Statement The information disclosure statement (IDS) filed on 11/22/2023 is in compliance with the provisions of 37 CFR 1.97. All references have been considered except where marked with a strikethrough. A signed copy of Form 1449 is included with this Office Action. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Specification Acknowledgement is made of the drawings received November 22, 2023. The drawings are objected to because: The entirety of FIG. 4 and FIG. 13 is blurry, so it is difficult to read and interpret the data. As recited in 37 CFR 1.84: (l) Character of lines, numbers, and letters. All drawings must be made by a process which will give them satisfactory reproduction characteristics. Every line, number, and letter must be durable, clean, black (except for color drawings), sufficiently dense and dark, and uniformly thick and well-defined. The weight of all lines and letters must be heavy enough to permit adequate reproduction. This requirement applies to all lines however fine, to shading, and to lines representing cut surfaces in sectional views. Lines and strokes of different thicknesses may be used in the same drawing where different thicknesses have a different meaning. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 2 is objected to because of the following informalities: a space should be inserted in “optionally 1-250mg per patient” (emphasis added) to recite “optionally 1-250 mg per patient”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3, 5, and 7-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1-2 are rejected as vague and indefinite for recitation of the phrase “pharmaceutically acceptable ester of D-cycloserine”. D-cycloserine has the structure shown below, and it is unclear where it is possible to form an ester. Thus, the claims are ambiguous. Claims 3, 5, and 7-12 are rejected for requiring and/or not clarifying the limitation at issue. PNG media_image1.png 199 266 media_image1.png Greyscale Claims 1-2 are rejected as vague and indefinite for the phrase “pharmaceutically acceptable precursor of D-cycloserine”. The term "precursor" renders claim 1 and claim 2 indefinite as precursor does not have a defined structure known in the art. For example, one could not ascertain as to which precursors are within the scope of the claim, resulting in unknown claimed compounds. Absent of specific compounds, Examiner suggests deleting this phrase. Claims 3, 5, and 7-12 are rejected for requiring and/or not clarifying the limitation at issue. Claims 1-2 are rejected as vague. The current claims recite a method of treating Major Depressive Disorder comprising administering adjunctive D-cycloserine. Is Applicant administering any amount (which could be suboptimal and have no therapeutic benefit), or a therapeutically effective amount? Examiner recommends adding a “therapeutically effective amount” into the claim language. Claims 3, 5, and 7-12 are rejected for requiring and/or not clarifying the limitation at issue. Moreover, the phrase, “optionally 1-250 mg per patient” is a vague since the treatment must be done with an effective amount. Claim 1 is vague and indefinite as claim 1 recites a method for treating MDD without reciting a subject or patient who is need of such treatment. Claim 2 is rejected to as vague and indefinite. It is unclear as to what kind of “patient” is receiving the method of treating. Examiner recommends amending the claim to recite “…in a patient in need thereof…” (emphasis added). Claims 3, 5, and 7-12 are rejected for requiring and/or not clarifying the limitation at issue. With regards to claim 3, the phrase “interest/lack” is vague. It is uncertain if the “/” is “and” or “or”, and the specification does not provide any clarity. Thus, said claim is ambiguous. Claims 5, 8, 10, and 12 are rejected as vague and indefinite for recitation of the phrase “wherein the low dose is a dose sufficient to achieve a plasma concentration of D-cycloserine of 1-30 µg/mL”. First, the claims currently recite “…the low dose is a dose…” and then do not proceed to provide an actual dose but rather the desired plasma concentrations after dose. This creates ambiguity because no dose is actually specified. Furthermore, the phrase “sufficient to achieve a plasma concentration of D-cycloserine of 1-30 µg/mL” is also vague and indefinite. What is sufficient to achieve said plasma concentration range? It is not possible to fully determine the range of doses that would lead to the result to be achieved claimed and for which protection is sought. This has the effect that a person skilled in the art cannot clearly decide which doses are to be covered by the claims and which are not. Therefore, the metes and bounds of said claims are unclear. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-3, and 7, 9, and 11 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. The analysis for adequate written description considers the following: (a) Actual reduction to practice; (b) Disclosure of drawings or structural chemical formulas; (c) Sufficient relevant identifying characteristics, such as (i) complete/partial structure, (ii) physical and/or chemical properties, and (iii) functional characteristics when coupled with known or disclosed correlation with structure; and (d) Representative number of samples. A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571,39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967). An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics. In particular, the specification as originally filed fails to provide sufficient written description on the bases of any of the agents demonstrating wherein possession of use of the following genus: “a pharmaceutically acceptable ester of D-cycloserine”, “an alkylated D-cycloserine”, and “pharmaceutically acceptable precursor of D-cycloserine”. The mere fact that Applicant may have a method of treating Major Depressive Disorder using D-cycloserine with transcranial magnetic stimulation is not sufficient to claim the entire genus of “a pharmaceutically acceptable ester of D-cycloserine”, “an alkylated D-cycloserine”, or “pharmaceutically acceptable precursor of D-cycloserine”. The claims lack written description because the terms “a pharmaceutically acceptable ester of D-cycloserine”, “an alkylated D-cycloserine”, and “pharmaceutically acceptable precursor of D-cycloserine” have substantial variance while the specification lacks sufficient variety of species to reflect the variance within the genus, and because of the lack of common structural attributes of the claimed genus, combined with a correlation between structure and function. The specification does not tell one of ordinary skill what variation is permitted by “a pharmaceutically acceptable ester of D-cycloserine”, “an alkylated D-cycloserine”, and “pharmaceutically acceptable precursor of D-cycloserine” and the different types of “a pharmaceutically acceptable ester of D-cycloserine”, “an alkylated D-cycloserine”, and “pharmaceutically acceptable precursor of D-cycloserine” are not be expected to act similarly. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]." Thus, claims 1-3, 7, 9, and 11 are rejected under 35 USC 112(a), (Written Description). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-3, 5, and 7-12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by NCT03937596 (first record publicly available May 6, 2019, cited on IDS filed 11/22/2023)(hereinafter, ‘NCT03937596’), as evidenced by Montgomery and Åsberg (MADRS) Depression Rating Scale (hereinafter, ‘MADRS’). NCT03937596 discloses a randomized, placebo-controlled clinical trial where adjunctive D-cycloserine was administered in conjunction with repetitive transcranial magnetic stimulation for the treatment of Major Depressive Disorder. The “Arms and Interventions” details that a daily oral dose of 100 mg D-cycloserine was administered. NCT03937596 discloses a primary outcome as a change in severity of depression symptoms as measured by MADRS. This test is a diagnostic questionnaire with questions directed to apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. A secondary outcome measure is a clinical remission of less than or equal to 10 on the MADRS scale, which indicates normal (no depression) to mild depression. Furthermore, Examiner notes that the phrases “to improve depressive symptoms and provide higher rates of clinical response and remission” (of claim 1) and “the dose is a dose of D-cycloserine sufficient to achieve a plasma concentration of D-cycloserine of 1-30 µg/mL” (of claims 5, 8, 10, and 12) do not require additional steps to be performed and simply expresses the intended result of carrying the process made obvious by the prior art: a method of treating MDD in a subject, comprising administrating adjunctive D-cycloserine with transcranial magnetic stimulation. MPEP 2111.04 states: “Claim scope is not limited by claim language that suggests or makes optional but does not require steps to be performed, or by claim language that does not limit a claim to a particular structure. However, examples of claim language, although not exhaustive, that may raise a question as to the limiting effect of the language in a claim are: (A) “ adapted to ” or “adapted for ” clauses; (B) “ wherein ” clauses; and (C) “ whereby ” clauses. The determination of whether each of these clauses is a limitation in a claim depends on the specific facts of the case. In Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005), the court held that when a “whereby’ clause states a condition that is material to patentability; it cannot be ignored in order to change the substance of the invention.” Id. However, the court noted (quoting Minton v. Nat ’l Ass ’n of Securities Dealers, Inc., 336 F.3d 1373, 1381, 67 USPQ2d 1614, 1620 (Fed. Cir. 2003)) that a “whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited” (emphasis added). In the instant case, the entirety of the phrases cited above in claims 1, 5, 8, 10, and 12 appear to be the result of the process made obvious by the prior art: a method of treating MDD, comprising administrating adjunctive D-cycloserine to augment transcranial magnetic stimulation, e. g. the intended result of a process step positively recited. Thus, each and every required element of the claims are taught, and the claims are anticipated. Conclusion All claims are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUKE ALAN BORALSKY whose telephone number is (571)272-9746. The examiner can normally be reached Monday - Friday 7:30 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /L.A.B./Examiner, Art Unit 1624 /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Nov 22, 2023
Application Filed
Oct 01, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741968
THERAPEUTIC AGENTS TARGETING GPR35
3y 8m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
99%
With Interview (+44.4%)
3y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 6 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month